AbbVie Inc. EBITDA Margin

EBITDA Margin of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including EBITDA Margin growth rates and interactive chart.


Highlights and Quick Summary

  • EBITDA Margin for the quarter ending March 30, 2021 was 50.37% (a 6.13% increase compared to previous quarter)
  • Year-over-year quarterly EBITDA Margin increased by 15.85%
  • Annual EBITDA Margin for 2020 was 48.25% (a 0.75% increase from previous year)
  • Annual EBITDA Margin for 2019 was 47.89% (a 12.82% increase from previous year)
  • Annual EBITDA Margin for 2018 was 42.45% (a -0.72% decrease from previous year)
  • Twelve month EBITDA Margin ending March 30, 2021 was 46.76% (a 1.52% increase compared to previous quarter)
  • Twelve month trailing EBITDA Margin increased by 3.93% year-over-year
Trailing EBITDA Margin for the last four month:
30 Mar '21 30 Dec '20 29 Sep '20 29 Jun '20
46.76% 46.06% 46.71% 44.99%
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EBITDA Margin of AbbVie Inc.

Most recent EBITDA Marginof ABBV including historical data for past 10 years.

Interactive Chart of EBITDA Margin of AbbVie Inc.

AbbVie Inc. EBITDA Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 50.37%
2020 47.46% 45.03% 43.48% 48.49% 48.25%
2019 51.3% 36.8% 47.27% 44.88% 47.89%
2018 -24.07% 43.64% 38.72% 42.2% 42.45%
2017 27.79% 43.93% 43.79% 42.54% 42.76%
2016 38.88% 41.43% 41.48% 42.73% 42.84%
2015 37.09% 35.53% 37.3% 36.61% 36.63%
2014 -4.07% 22.95% 34.86% 33.97% 21.03%
2013 33.95% 34.46% 36.0% 35.39% 34.92%
2012 40.91% 40.44% 38.22% 31.08% 37.91%
2011 -114.35% 107.15% 107.43% 29.23% 28.04%
2010 37.74%

Business Profile of AbbVie Inc.

Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.